Genomic Profiling Provides Much-Needed Prognostic Data in Glioma
Low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.
Avastin After Recurrence in Glioblastoma Shows No Benefit
Continuing Avastin (bevacizumab) in patients with recurrent glioblastoma after progression of the disease does not improve patient outcomes, according to results from the phase 2 CABARET trial.
Immunotherapy Combination Extends Survival for Patients With Relapsed Glioblastoma
Adding the immunotherapeutic vaccine Rintega (rindopepimut) to Avastin (bevacizumab) may help boost survival in patients with a genetic subtype of glioblastoma associated with poor outcomes.